MXCT News and Press, MaxCyte Inc. From 03/22/22

GAITHERSBURG, Md., March 22, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery...

Raymond James has initiated Nkarta (NASDAQ:NKTX) with a buy rating citing the company's allogenic natural killer cell therapy platform for cancer. The firm has a $17 price target (~69% upside based on Thursday's close). Analyst Dane Leone said that he believes the natural killer platform has ...

On Wednesday, life sciences company, MaxCyte (NASDAQ:MXCT) announced the appointment of Dr. Cenk Sumen as its new Chief Scientific Officer. Prior to his appointment, Sumen served Stemson Therapeutics as the Chief Technology Officer, and before that, he has worked for companies including Therm...

GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic disco...

GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic disco...

The following slide deck was published by MaxCyte, Inc. in conjunction with this event. For further details see: MaxCyte (MXCT) Investor Presentation - Slideshow

GAITHERSBURG, Md., Feb. 11, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discov...

MaxCyte (NASDAQ:MXCT) signed a strategic platform license (SPL) with Intima Bioscience, a biotech developing genetically engineered cell therapies for solid tumor cancer. Under the terms of the agreement, Intima obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow...

NEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Intima Bioscience, Inc....

Fourth quarter 2021 revenue expected to be greater than $10 million Full year 2021 revenue expected to be greater than $33.7 million Installed base of greater than 500 instruments 15 SPLs, covering more than 95 programs, of which over 15% have enter...